Patent US4401592A successfully refreshed from Google Patents.
US4401592A
Expired / Lapsed
US
⏱️ 0.0 years remaining
Pharmaceutical composition having antitumor activity
Assignee: Kureha Corp
•
Filing: 1981-11-16
•
Granted: 1983-08-30
•
Expires: 2001-11-16
Abstract
Abstract Disclosed is a novel pharmaceutical composition having antitumor (anti-cancer) activity without causing pyrexia and anaphylaxis, formed by an amide bonding between an antibody obtained by the purification of the antibody to tumor (cancer) antigen via affinity-chromatography and an antitumor substance (anti-cancer drug).
Inventors
- 👤 Chikao Yoshikumi
- 👤 Takayoshi Fujii
- 👤 Masahiko Fujii
- 👤 Kenichi Matsunaga
- 👤 Yoshiharu Oguchi
- 👤 Koichi Niimura
Bibliographic Details
Application Number
—
Jurisdiction
US
Data Source
google_patents
Last Synchronized
2026-10-29 12:13
CPC Classifications
A; A61; A61K; A61K47/00; A61K47/50; A61K47/51; A61K47/68; A61K47/6801; A61K47/6803; A61K47/6807; A61K47/6809; Y; Y10; Y10S; Y10S530/00; Y10S530/806; Y10S530/81; Y10S530/812; Y10S530/813
Claims Analysis
Total Claims: 10
Claim 1
Independent Claim
87 words
A pharmaceutical composition is dosage unit form for use in the treatment of cancer, which comprises a therapeutically effective amount of a substance bonded by amide bonding an anti-cancer drug having at least one amino group or carboxyl group, selected from the group consisting of antibiotic substances, antimetabolitic substances and alkylating agents with an anti-cancer antibody obtained by purifying immunogloubulin fraction with affinity-chromatography, in the presence of a reagent selected from the group consisting of thionyl chloride, diethyl phosphorocyanidate and a carbodiimide, and a pharmaceutically acceptable carrier.
Claim 2
Dependent Claim
87 words
A pharmaceutical composition is dosage unit form for use in the treatment of cancer, which comprises a therapeutically effective amount of a substance bonded by amide bonding an anti-cancer drug having at least one amino group or carboxyl group, selected from the group consisting of antibiotic substances, antimetabolitic substances and alkylating agents with an anti-cancer antibody obtained by purifying immunogloubulin fraction with affinity-chromatography, in the presence of a reagent selected from the group consisting of thionyl chloride, diethyl phosphorocyanidate and a carbodiimide, and a pharmaceutically acceptable carrier.
Claim 3
Dependent Claim
28 words
A pharmaceutical composition according to claim 1, wherein said antibiotic substance is selected from the group consisting of mitomycin C, doxorubicin hydrochloride, bleomycin, daunorubicin, actinomycin D and sarkomycin.
Claim 4
Dependent Claim
25 words
A pharmaceutical composition according to claim 1, wherein said antimetabolitic substance is selected from the group consisting of cytarabine, 8-azaguanine, 5-fluorouracil, methotrexate and sodium aminopterin.
Claim 5
Dependent Claim
24 words
A pharmaceutical composition according to claim 1, wherein said alkylating agent is selected from the group consisting of chlorambucil, melphalan, uramustine, ACNU and cyclophosphamide.
Claim 6
Dependent Claim
18 words
A pharmaceutical composition according to claim 1, wherein said anti-cancer antibody is an anti-cancer alloantibody purified by affinity-chromatography.
Claim 7
Dependent Claim
55 words
A pharmaceutical composition according to claim 1, wherein the amino group or the carboxyl group of said anti-cancer drug is introduced thereinto by bringing the anti-cancer drug into reaction with a compound having the formula: X(CH.sub.2).sub.n COOH wherein X represents an atom of chlorine or bromine and n denotes an integer of 1 to 3.
Claim 8
Dependent Claim
56 words
A pharmaceutical composition according to claim 1, wherein the amino group or the carboxyl group of said anti-cancer drug is introduced thereinto by bringing the anti-cancer drug into reaction with a compound having the formula: HCl.NH.sub.2 (CH.sub.2).sub.n COX wherein X represents an atom of chlorine or bromine and n denotes an integer of 1 to 3.
Claim 9
Dependent Claim
25 words
A pharmaceutical composition according to claim 1, wherein said affinity-chromatography is performed by using a carrier to which molecules of the cancer antigen are bound.
Claim 10
Dependent Claim
15 words
A pharmaceutical composition according to claim 8, wherein said carrier is packed into a column.
References Cited (Backward Citations)
AT300193B
Cited
CH548776A
Cited
US3917818A
Cited
CH572745A5
Cited
US3983001A
Cited
US4160018A
Cited
US3947352A
Cited
GB1509707A
Cited
FR2362119B1
Cited
US4046722A
Cited
US4195017A
Cited
FR2312259B1
Cited
US4093607A
Cited
US4263279A
Cited
FR2323147B1
Cited
US4017471A
Cited
GB1541436A
Cited
US4123427A
Cited
US4275000A
Cited
US4228237A
Cited
US4315851A
Cited
US4223005A
Cited
USPTO Annuity & Maintenance Windows
| Annuity Stage | Window Opens | Payment Deadline | Surcharge Period Until | Estimated Fee | Status |
|---|---|---|---|---|---|
| 3.5 Years (Year 4) | 1986-08-29 | 1987-02-28 | 1987-08-30 | $2000.00 | Window Closed / Lapsed |
| 7.5 Years (Year 8) | 1990-08-29 | 1991-02-28 | 1991-08-30 | $3760.00 | Window Closed / Lapsed |
| 11.5 Years (Year 12) | 1994-08-29 | 1995-02-28 | 1995-08-30 | $7700.00 | Window Closed / Lapsed |